The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with all features of the metabolic syndrome. Although deposition of excess triglycerides within liver cells, a hallmark of NAFLD, is associated with a loss of insulin sensitivity, it is not clear which cellular abnormality arises first. We have explored this in mice overexpressing carbohydrate responsive element-binding protein (ChREBP). On a standard diet, mice overexpressing ChREBP remained insulin sensitive, despite increased expression of genes involved in lipogenesis/fatty acid esterification and resultant hepatic steatosis (simple fatty liver). Lipidomic analysis revealed that the steatosis was associated with increased accumulation of monounsaturated fatty acids (MUFAs). In primary cultures of mouse hepatocytes, ChREBP overexpression induced expression of stearoyl-CoA desaturase 1 (Scd1), the enzyme responsible for the conversion of saturated fatty acids (SFAs) into MUFAs. SFA impairment of insulin-responsive Akt phosphorylation was therefore rescued by the elevation of Scd1 levels upon ChREBP overexpression, whereas pharmacological or shRNA-mediated reduction of Scd1 activity decreased the beneficial effect of ChREBP on Akt phosphorylation. Importantly, ChREBP-overexpressing mice fed a high-fat diet showed normal insulin levels and improved insulin signaling and glucose tolerance compared with controls, despite having greater hepatic steatosis. Finally, ChREBP expression in liver biopsies from patients with nonalcoholic steatohepatitis was increased when steatosis was greater than 50% and decreased in the presence of severe insulin resistance. Together, these results demonstrate that increased ChREBP can dissociate hepatic steatosis from insulin resistance, with beneficial effects on both glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In this regard, ChREBP expression in liver biopsies from patients with MASH was observed to be two-fold higher when the histologic steatosis score was greater than 50% compared to those with less than 50%.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
The cited source says what the claim attributes to it.
In the citing paper
“However, it decreased in the presence of severe IR [34,94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Taken together, these findings demonstrate that ChREBP-driven hepatic steatosis can be dissociated from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“genes was achieved by the ΔΔCt method (88).”
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“(91): 0, absent; 1, <5%; 2, 5%–33%; 3, 33%–66%; 4, >66%.”
Signal integration in the endoplasmic reticulum unfolded protein response
Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,296 · cited 1×
“UPR induces transcription of a set of genes whose protein products increase the capacity for protein folding and ER-associated degradation and induces apoptosis when the ER function is severely impaired (41, 42).”
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 11×
“To our knowledge, our work is the first to report that hepatic ChREBP expression varies positively according to the degree of steatosis and inversely to insulin resistance in a cohort of patients with NASH.”
InfluentialDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“Using a multiple-stable-isotope approach, Don-nelly et al. (16) estimated that, of the TG content accounted for in the livers of patients with NAFLD, 60% arose from NEFA, a little over 10% came from the diet, and close to 30% came from de novo lipogenesis, underlying the importance of de novo TG synthesis in the etiol…”
InfluentialNutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075 · cited 17×
“Recent studies have revealed that chronic SFA exposure activates unfolded protein response (UPR) in cultured cells (39, 40).”
InfluentialPGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624 · cited 1×
“In the liver, SIRT1 controls gluconeogenic activity by modulating the acetylation levels of a network of transcription factors and/or coactivators, including PPARGC1A (74–76).”
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · cited 1×
“We also measured the expression of fibroblast growth factor 21 (FGF21), a key metabolic regulator whose expression is regulated via PPAR pathways during states requiring increased fatty acid oxidation (33).”
Research works printed but not linked: 2
- Denechaud, 2008, J Clin Invest., 118, 956
- Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes . 2006;55(8):2159-2170. · DOI · Paper page
Cited by
Items 201–300 of 405
Effect of high-intensity exercise and high-fat diet on lipid metabolism in the liver of rats
Suk, M., & Shin, Y. (2015) · Physical Activity and Nutrition · doi:10.5717/jenb.2015.15122303 · Cited by 33
“In a previous study, ChREBP expression had beneficial effects on insulin signaling and blood glucose level, possibly resulting from an exercise-induced increase in glycolysis [34].”
BackgroundDaniel, P. V., Dogra, S., Rawat, P., Choubey, A., Khan, A. S., Rajak, S., Kamthan, M., & Mondal, P. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100714 · Cited by 34
Katz, L. S., Xu, S., Ge, K., Scott, D. K., & Gershengorn, M. C. (2017) · Endocrinology · doi:10.1210/en.2017-00579 · Cited by 31
Xu, G., Quan, S., Schell, J. R., Gao, Y., Varmazyad, M., Sreenivas, P., Cruz, D., Jiang, H., Pan, M., Han, X., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj5942 · Cited by 35
Fatty acids regulation of inflammatory and metabolic genes
Masi, L. N., Rodrigues, A. C., & Curi, R. (2013) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32836236df · Cited by 29
Chan, S. M. H., Zeng, X., Sun, R., Jo, E., Zhou, X., Wang, H., Li, S., Xu, A., Watt, M. J., & Ye, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.04.005 · Cited by 27
Nischarin inhibition alters energy metabolism by activating AMP-activated protein kinase
Dong, S., Baranwal, S., García, A., Serrano-Gomez, S. J., Eastlack, S. C., Iwakuma, T., Mercante, D. E., Mauvais‐Jarvis, F., & Alahari, S. K. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784256 · Cited by 25
“expression level was analyzed using the 2 Ct method (51).”
MethodInsulin activates hepatic Wnt/β-catenin signaling through stearoyl-CoA desaturase 1 and Porcupine
Cabrae, R., Dubuquoy, C., Caüzac, M., Morzyglod, L., Guilmeau, S., Noblet, B., Fève, B., Postic, C., Burnol, A., & Moldes, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-61869-4 · Cited by 26
Self-citationBetaine Alleviates Hypertriglycemia and Tau Hyperphosphorylation in db/db Mice
Jung, G.-Y., Won, S. B., Kim, J., Jeon, S., Han, A., & Kwon, Y. H. (2013) · Toxicological Research · doi:10.5487/tr.2013.29.1.007 · Cited by 26
“Previous studies have reported that fatty acid composition, rather than fatty acid oversupply, is related to insulin sensitivity (26,27).”
BackgroundMaciejewska, D., Marlicz, W. M., Ryterská, K., Banaszczak, M., Jamioł-Milc, D., & Stachowska, E. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/5856201 · Cited by 28
Kim, J. K., Lee, K. S., Chang, H. Y., Lee, W. K., & Lee, J. I. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-186 · Cited by 28
“ChREBP, which is also suspected to be modulated by KLF10 [27], is a transcription factor that is observed to play a protective role in insulin resistance although it would aggravate simple hepatic steatosis [26].”
BackgroundIizuka, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112058 · Cited by 39
“In the liver, hepatic Chrebp overexpression evoked fatty liver [78,79], and the suppression of ChREBP in obese mice prevented body weight gain and fatty liver [80,81].”
BackgroundStephenson, E. J., Stayton, A. S., Sethuraman, A., Rao, P., Meyer, A., Gomes, C., Mulcahy, M. C., McAllan, L., Puchowicz, M. A., Pierre, J. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33840-6 · Cited by 33
Ducheix, S., Podechard, N., Lasserre, F., Polizzi, A., Pommier, A., Murzilli, S., Lisio, C. D., D’Amore, S., Bertrand‐Michel, J., Montagner, A., et al. (2012) · Biochimie · doi:10.1016/j.biochi.2012.09.028 · Cited by 31
Self-citationMechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
“Studies indicate that DNL contributes approximately 26% of FFA in MASLD patients, accompanied by increased expression of SREBP-1c and ChREBP [14, 21].”
Endocrine Fibroblast Growth Factors in Relation to Stress Signaling
Shimizu, M., & Sato, R. (2022) · Cells · doi:10.3390/cells11030505 · Cited by 27
Multifaceted Nature of Lipid Droplets in Viral Interactions and Pathogenesis
Huitron, L. H.-M., Jesús‐González, L. A. D., Castillo, M. M., Ulloa-Aguilar, J. M., Cabello-Gutiérrez, C., Helguera‐Repetto, A. C., García‐Cordero, J., & León‐Juárez, M. (2023) · Microorganisms · doi:10.3390/microorganisms11071851 · Cited by 25
“It is estimated that this condition affects up to one-third of the world’s population [76,77].”
BackgroundZhang, Y., Li, C., Li, X., Wu, C., Zhou, H., Lu, S., & Liu, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11309 · Cited by 24
Liver-Derived S100A6 Propels β-Cell Dysfunction in NAFLD
Dogra, S., Das, D., Maity, S. K., Paul, A., Rawat, P., Daniel, P. V., Das, K., Mitra, S., Chakrabarti, P., & Mondal, P. (2022) · Diabetes · doi:10.2337/db22-0056 · Cited by 25
Tissue Specific Effects of Dietary Carbohydrates and Obesity on ChREBPα and ChREBPβ Expression
Stamatikos, A., da Silva, R. P., Lewis, J. T., Douglas, D. N., Kneteman, N. M., Jacobs, R. L., & Paton, C. M. (2015) · Lipids · doi:10.1007/s11745-015-4090-0 · Cited by 29
“The lipogenic target stearoylCoA desaturase-1 (SCD-1), another known target gene of ChREBP [16, 17], was also increased by refeeding CHO.”
BackgroundREDD1 deficiency protects against nonalcoholic hepatic steatosis induced by high‐fat diet
Dumas, K., Ayachi, C., Gilleron, J., Lacas‐Gervais, S., Pastor, F., Favier, F. B., Peraldi, P., Vaillant, N., Yvan‐Charvet, L., Bonnafous, S., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201901799rr · Cited by 26
Liu, J., Shi, Y., Peng, D., Wang, L., Yu, N., Wang, G., & Chen, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.842980 · Cited by 26
“observed that ChREBP expression is increased in patients with NASH, 50% decreased in livers of severe insulin resistance patients, which suggested that ChREBP-mediated steatosis is not strongly associated with high insulin resistance (185), so it is uncertain whether ChREBP would be a viable target for therapeutics of…”
BackgroundMin, R. W. M., Aung, F. W. M., Liu, B., Arya, A., & Win, S. (2022) · Biomedicines · doi:10.3390/biomedicines10082035 · Cited by 24
The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease
Munteanu, C., & Schwartz, B. (2023) · Antioxidants · doi:10.3390/antiox12040903 · Cited by 30
Jiang, M., & Xie, W. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.743561 · Cited by 24
“Although the uncoupling of hepatic steatosis from IR has been suggested by recent data (Benhamed et al., 2012; Monetti et al., 2007), the genetic mutations used in these studies may not represent the normal pathogenesis and progression of hepatic steatosis.”
BackgroundSong, Z., Yang, H., Zhou, L., & Yang, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205132 · Cited by 26
“ChREBP liv rspecific overexpression Standard diet = = [67]”
BackgroundInfluentialLine, M., Bindesb⊘ll, C., & Hilde, I. (2013) · InTech eBooks · doi:10.5772/51357 · Cited by 27
“Benhamed et al (Benhamed et al., 2012) also showed that ChREBP expression was increased in liver biopsies from patients with steatosis and decreased in liver of patients with severe insulin resistance, suggesting that ChREBP, alone or in combination with LXR, drives SCD1 expression and steatosis…”
BackgroundInfluentialKakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 28
Yu, J. H., Lee, Y. J., Kim, H. J., Choi, H., Choi, Y., Seok, J. W., & Kim, J. W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.03.095 · Cited by 26
Kim, G.-Y., Lee, Y., Cho, J., Pan, C., Jun, H. S., Springer, D., Mansfield, B. C., & CHOU, J. Y. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv230 · Cited by 21
“D ow nloaded from https://academ ic.oup.com /hm g/article-abstract/24/18/5115/687597 by guest on 03 January 2019 that mice overexpressing hepatic ChREBP along with increased SCD1 exhibit improved insulin signaling that correlates with phosphorylation and activation of protein kinase B/Akt (8).”
BackgroundInfluentialGaray-Lugo, N., Domínguez‐López, A., Miliar-García, Á., Barrera, E. S. A., Gómez‐López, M., Alcalá, A. G., Martínez–Godínez, M. D. L. Á., & Lara‐Padilla, E. (2016) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2016.1208221 · Cited by 23
Ducheix, S., Vegliante, M. C., Villani, G., Napoli, N., Sabbà, C., & Moschetta, A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2331-x · Cited by 26
Liver-directed gene therapy for murine glycogen storage disease type Ib
Kwon, J. H., Lee, Y., Cho, J., Kim, G., Anduaga, J., Starost, M. F., Mansfield, B. C., & CHOU, J. Y. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx325 · Cited by 22
Raveendran, V. V., Kassel, K. M., Smith, D. D., Luyendyk, J. P., Williams, K. J., Cherian, R., Reed, G. A., Flynn, C. A., Csanaky, I. L., Lickteig, A. J., et al. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00027.2014 · Cited by 21
Exercise regulation of hepatic lipid droplet metabolism
la Fuente, F. P.-D., Bórquez, J. C., Díaz‐Castro, F., Espinosa, A., Chiong, M., & Troncoso, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120522 · Cited by 21
Ducheix, S., Piccinin, E., Peres, C., García‐Irigoyen, O., Bertrand‐Michel, J., Fouache, A., Cariello, M., Lobaccaro, J. A., Guillou, H., Sabbà, C., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2053 · Cited by 20
“[31] It has already been shown that MUFAs displayed beneficial effects in liver: their accumulation during steatosis is dissociated from inflammation or insulin resistance.[32,33] Moreover, in a NASH model induced by dietary choline/methionine deficiency, Scd1 deletion in the whole organism favored hepatic damages des…”
BackgroundSelf-citationAl-attar, R., Wu, C., Biggar, K. K., & Storey, K. B. (2019) · Physiological and Biochemical Zoology · doi:10.1086/706463 · Cited by 19
“The carbohydrate-responsive element-binding protein (ChREBP) is a highly conserved glucose-sensitive transcription factor that canbe found inmanymammalian tissues (Yamashita et al. 2001; Benhamed et al. 2012; Herman et al. 2012).”
BackgroundYahya, M. A., Alshammari, G. M., Osman, M. A., Al‐Harbi, L. N., Yagoub, A. E. A., & AlSedairy, S. A. (2022) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2022.2102654 · Cited by 20
“Overexpressing SREBP1/2 and ChREBP induced NAFLD in rodents (Benhamed et al .”
Mechanism of the effect of glycosyltransferase GLT8D2 on fatty liver
Zhan, Y., Zhao, F., Xie, P., Zhong, L.-P., Li, D., Gai, Q., Li, L., Wei, H., Zhang, L., & An, W. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0040-3 · Cited by 21
“NAFLD is characterized by the excessive accumulation of triglyceride in hepatocytes [18].”
BackgroundOh, A., Jeong, Y., Yu, J., Dao, T., Kang, J. K., Jung, Y. H., Im, S., Lee, S. B., Ryu, D., Pajvani, U. B., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.11.019 · Cited by 22
Rodríguez, M. J., Herrera, F., Donoso, W., Castillo, I., Orrego, R., González, D. R., & Zúñiga‐Hernández, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228827 · Cited by 18
“In CLD, it is commonly believed that simple steatosis is the benign, while NASH is progressive with marked increase in liver-related mortality due to cirrhosis or HCC and HCC is common in patients with fibrotic NASH and NASH related cirrhosis [51].”
BackgroundInfluentialPAS Kinase deficiency alters the glucokinase function and hepatic metabolism
Pérez-García, A., Dongil, P., Hurtado-Carneiro, V., Blázquez, E., Sanz, C., & Álvarez, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-29234-8 · Cited by 21
López‐Pastor, A. R., Gómez‐Hernández, A., Díaz-Castroverde, S., González‐Aseguinolaza, G., Gonzalez-Rodriguez, A., Garcia, G., Fernández, S., Escribano, Ó., & Benito, M. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.036186 · Cited by 18
“…fatty acids (SFAs), and that an increase in the MUFA/ SFA ratio has been correlated with an improvement in both glucose and lipid metabolism (Benhamed et al., 2012), the increase in Scd1 mRNA levels observed in HFD-IRA mice, together with the decrease in Fasn and Pgc1a mRNA levels, could…”
Causative and Sanative dynamicity of ChREBP in Hepato-Metabolic disorders
Daniel, P. V., & Mondal, P. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151128 · Cited by 27
Signal Transduction and Molecular Regulation in Fatty Liver Disease
Dong, X. C., Chowdhury, K., Huang, M., & Kim, H.-G. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0076 · Cited by 23
“Hepatic ChREBP overexpression in mice leads to increased hepatic steatosis but improved insulin signaling on a high-fat diet (14).”
Liu, A., Huang, M., Xi, Y., Deng, X., & Xu, K. (2025) · Biomedicines · doi:10.3390/biomedicines13061422 · Cited by 17
Agrahari, A. K., Dikshit, M., & Asthana, S. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.008 · Cited by 18
Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD)
Singh, S., Kumar, A., Gupta, S., & Agrawal, R. (2023) · Tissue Barriers · doi:10.1080/21688370.2023.2289830 · Cited by 20
“44 In addition to catalyzing DNL, aceltyl-CoA carboxylase (ACC) controls mitochondrial FAO.”
InfluentialMa, L., Yan-Yan, Y. U. A. N., Zhao, M. H., Zhou, X., Jehangir, T., Wang, F.-Y., Yang, X., & Bu, S. (2018) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(18)30074-8 · Cited by 18
Salamanca, A., Bárcena, B., Arribas, C., Fernández‐Agulló, T., Martínez, C., Carrascosa, J. M., Ros, M., Andrés, A., & Gallardo, N. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.05.009 · Cited by 21
“In fact, recent data show that ChREBP overexpressing mice fed a high-fat diet are characterized by increased expression of genes involved in lipogenesis, fatty acid esterification and TAG mobilization, such as ACC-α, FAS, DGAT-1 and MTTP, leading to hepatic steatosis (Benhamed et al., 2012).”
BackgroundRamamonjisoa, N., Ratiney, H., Mutel, E., Guillou, H., Mithieux, G., Pilleul, F., Rajas, F., Beuf, O., & Cavassila, S. (2013) · Journal of Lipid Research · doi:10.1194/jlr.d033399 · Cited by 22
Self-citationRabbani, N., & Thornalley, P. J. (2025) · Clinical Science · doi:10.1042/cs20257727 · Cited by 17
“This allows for safer hepatic storage with decreased risk of insulin resistance and steatohepatitis but still supports hepatic steatosis [121].”
InfluentialPak1 mediates the stimulatory effect of insulin and curcumin on hepatic ChREBP expression
Zeng, K., Tian, L., Sirek, A., Shao, W., Liu, L., Chiang, Y., Chernoff, J., Ng, D. S., Weng, J., & Jin, T. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx031 · Cited by 16
Ipsen, D. H., Skat‐Rørdam, J., Tsamouri, M. M., Latta, M. R., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2019) · Molecular Genetics and Genomics · doi:10.1007/s00438-019-01537-z · Cited by 17
Dietary Macronutrient Composition Directs ChREBP Isoform Expression and Glucose Metabolism in Mice
Jois, T., HOWARD, V. G., Youngs, K., Cowley, M. A., & Sleeman, M. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168797 · Cited by 17
Effects of Quercetin on the Intestinal Microflora of Freshwater Dark Sleeper Odontobutis potamophila
Zhu, C., Liu, G., Gu, X., Zhang, T., Xia, A., Zheng, Y., Yin, J., Han, M., & Jiang, Q. (2022) · Antioxidants · doi:10.3390/antiox11102015 · Cited by 15
“Metabolic dysregulation can eventually lead to hepatic steatosis because obesity impairs hepatic glucose and lipid homeostasis [42,43].”
BackgroundThe Function of MondoA and ChREBP Nutrient—Sensing Factors in Metabolic Disease
Ahn, B. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108811 · Cited by 18
Obesity and Metabolic Dysfunction-associated Fatty Liver Disease: Understanding the Intricate Link
Vulchi, J., Suryadevara, V., Mohan, P., Kamalanathan, S., Sahoo, J., Naik, D., & Selvarajan, S. (2023) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00043 · Cited by 22
The Role of Mondo Family Transcription Factors in Nutrient-Sensing and Obesity
Ke, H., Luan, Y., Wu, S., Zhu, Y., & Tong, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.653972 · Cited by 15
“Liver-specific overexpression = ↘ ↗ = (35)”
BackgroundNutrigenomics: linking food to genome
Jabeen, A., Malik, G., Mir, J. I., & Rasool, R. (2023) · Italian Journal of Food Science · doi:10.15586/ijfs.v35i1.2262 · Cited by 16
Nagarajan, S. R., Livingstone, E. J., Monfeuga, T., Lewis, L. C., Ali, S. H. L., Chandran, A., Dearlove, D., Neville, M. J., Chen, L., Maroteau, C., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155563 · Cited by 15
“Mice with ChREBP overexpression had lower blood glucose following insulin and pyruvate tolerance tests, despite higher expression of DNL genes and IHTG accumulation; however, the effect on pAKT expression was in contrast to our study [6].”
BackgroundResultInfluentialMercurio, G., Giacco, A., Scopigno, N., Vigliotti, M., Goglia, F., Cioffi, F., & Silvestri, E. (2025) · Nutrients · doi:10.3390/nu17071214 · Cited by 22
“The elevated levels of SREBP-1c and ChREBP found in liver tissue analyses from NAFLD patients highlight their role in promoting TG accumulation and disease progression [32,33].”
Gondoin, A., Hampe, C., Eudes, R., Fayolle, C., Pierre‐Eugène, C., Miteva, M. A., Villoutreix, B. O., Charnay‐Pouget, F., Aitken, D. J., Issad, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17122-6 · Cited by 14
Song, L., Zhou, H., Yu, W., Ding, X., Yang, L., Wu, J., & Song, C. (2020) · Journal of Medicinal Food · doi:10.1089/jmf.2019.4468 · Cited by 15
“27 A previous study indicated that incubation of hepatocytes with saturated FAs decreased cell viability, while incubation with mono-unsaturated FAs has no influence.”
The glucose-sensing transcription factor ChREBP is targeted by proline hydroxylation
Heidenreich, S., Weber, P., Stephanowitz, H., Petricek, K. M., Schütte, T., Oster, M., Salo, A. M., Knauer, M., Göhring, I., Yang, N. Y., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014402 · Cited by 17
“Similarly, liver-specific expression of an active ChREBP mutant in mice improves insulin signaling and glucose tolerance, despite greater hepatic steatosis (8).”
BackgroundFernández, A., Mazuecos, L., Pintado, C., Rubio, B., López, V., Solís, A. J. D., Rodríguez-Pérez, M., Andrés, A., & Gallardo, N. (2019) · Nutrients · doi:10.3390/nu11081865 · Cited by 17
“ChREBP, in liver, promotes lipogenesis and fatty acid esterification [19,29], whereas in adipocytes, regulates the expression of PPARγ target genes involved in thermogenesis and promotes insulin sensitivity [29].”
BackgroundCrosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Gowda, D., Shekhar, C., Gowda, S. G. B., Chen, Y., & Hui, S. (2023) · Livers · doi:10.3390/livers3040045 · Cited by 15
“Adenovirus-mediated ChREBP overexpression in high-fat-fed mice led to hepatic steatosis and elevated DNL [107].”
de Melo, D. G., Rodrigues, V. C. D. C., Pereira, G. J. D. S., de Campos, T. D. P., Canciglieri, R. D. S., Pauli, J. R., da Silva, A. S. R., Fernandes, C. J. D. C., & de Moura, L. P. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122567 · Cited by 13
Targeting hepatocyte carbohydrate transport to mimic fasting and calorie restriction
Kading, J. C., Finck, B. N., & DeBosch, B. J. (2020) · FEBS Journal · doi:10.1111/febs.15482 · Cited by 13
Jois, T., & Sleeman, M. W. (2017) · Journal of Neuroendocrinology · doi:10.1111/jne.12473 · Cited by 16
Zhang, D., Zhao, Y., Zhang, G., Lank, D. S., Cooke, S., Wang, S., Nuotio-Antar, A. M., Tong, X., & Yin, L. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101957 · Cited by 14
“Moreover, another study showed that hepatic ChREBP was increased in patients with liver steatosis but decreased in patients with severe insulin resistance [68], consistent with our time-course study of NASH diet feeding.”
ResultShimizu, H., Lu, Y., Vella, K. R., Damilano, F., Astapova, I. I., Amano, I., Ritter, M. J., Gallop, M. R., Rosenzweig, A. N., Cohen, R., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220717 · Cited by 13
Casteras, S., Abdul-Wahed, A., Soty, M., Vulin, F., Guillou, H., Campaña, M. B., Stunff, H. L., Pirola, L., Rajas, F., Mithieux, G., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4097-y · Cited by 14
“It is of note that all mouse models exhibiting a dissociation between hepatic steatosis and insulin resistance are characterised by an increase in hepatic FGF21 levels and MUFA/SFA ratio, and are never associated with an increase in HGP [2, 3, 6].”
BackgroundSelf-citationLou, J., Li, C., Li, Z., Zhang, T., Chen, Z., & Bian, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.164 · Cited by 12
FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism
Zhao, F., Zhang, L., Zhang, M., Huang, J., Zhang, J., & Chang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.850128 · Cited by 11
“In contrast, overexpression of ChREBP in the liver of mice resulted in worsening of hepatic steatosis (Benhamed et al., 2012).”
BackgroundSkinner, C. M., Miousse, I. R., Ewing, L., Sridharan, V., Cao, M., Lin, H., Williams, D. K., Avula, B., Haider, S., Chittiboyina, A. G., et al. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.09.067 · Cited by 13
“In addition, Chrebp overexpression substantially worsens hepatic steatosis in mice (Benhamed et al., 2012), while inhibition of Chrebp in obese ob/ob mice can reverse hepatic steatosis (Dentin et al.”
BackgroundTan, Y., Hu, Y., Yang, Y., & Chu, H. (2025) · MedComm · doi:10.1002/mco2.70532 · Cited by 15
New insights into the inter-organ crosstalk mediated by ChREBP
Carbinatti, T., Régnier, M., Parlati, L., Benhamed, F., & Postic, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095440 · Cited by 14
“Indeed, Chrebp expression is increased in liver of ob/obmice with hepatic steatosis (21) and in human liver from patients developing simple hepatic steatosis and non-alcoholic steatohepatitis (23, 101).”
BackgroundSelf-citationPang, M. D., Bastings, J. J. A. J., Bruls, Y. M. H., Harrold, J. A., Kjølbæk, L., Halford, J. C. G., Adam, T. C., Raben, A., Schrauwen‐Hinderling, V. B., Goossens, G. H., et al. (2023) · Obesity · doi:10.1002/oby.23773 · Cited by 12
ChREBP refines the hepatic response to fructose to protect the liver from injury
Hall, A. M., & Finck, B. N. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95008 · Cited by 10
Fan, S., Wang, Y., Wang, C., Jin, H., Wu, Z., Lu, J. L., Zhang, Z., Sun, C., Shan, Q., Wu, D., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.04.003 · Cited by 10
Santos, F., Correia, B. R. O., Marinho, T. D. S., Barbosa‐da‐Silva, S., Mandarim‐de‐Lacerda, C. A., & Souza‐Mello, V. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110804 · Cited by 12
Kawata, S., Nakamura, A., Miyoshi, H., Yang, K., Shigesawa, I., Yamauchi, Y., Tsuchida, K., Omori, K., Takahashi, K., Nomoto, H., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14586 · Cited by 11
“Although this results in a hypoglycaemic effect, the consequent metabolites would repress the hypoglycaemic effect because of the repression of glucokinase activity by Chrebp.”
BackgroundInfluentialSomvanshi, P. R., Patel, A. K., Bhartiya, S., & Venkatesh, K. V. (2016) · RSC Advances · doi:10.1039/c5ra18128c · Cited by 9
Gong, K., Zhang, Z., Chen, S., Zhu, X., Wang, M.-Y., Yang, X., Ding, C., Han, J., Li, Q., & Duan, Y. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01121-7 · Cited by 9
“Excess FFA resulting from unlimited carbohydrate intake has lipotoxicity promoting the progression of NAFLD [43, 44].”
BackgroundZhang, Y., Luo, Y., Liu, X., Kiupel, M., Li, A., Wang, H., Mi, Q., & Xiao, H. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.007 · Cited by 9
“13 – 15 Among them, the mRNA level of Pparg2 was signi fi cantly increased in the livers of 10-month-old Ncoa5 D M/ þ mice compared with age-matched Ncoa5 fl / þ male mice (Figure 4 A ).”
BackgroundAlterations of Central Liver Metabolism of Pediatric Patients with Non-Alcoholic Fatty Liver Disease
Berndt, N., Hudert, C. A., Eckstein, J., Loddenkemper, C., Henning, S., Bufler, P., Meierhofer, D., Sack, I., Wiegand, S., Wallach, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911072 · Cited by 10
“Therefore, the transcription factors SREBP1 and ChREBP are key regulators of pro-lipogenic genes [28].”
BackgroundNew mechanisms contributing to hepatic steatosis: glucose, insulin, and lipid signaling
Lee, Y. J., Yu, J. H., Kim, W., & Kim, J. W. (2014) · Animal Cells and Systems · doi:10.1080/19768354.2014.906502 · Cited by 11
“Expression of hepatic ChREBP, which promotes conversion of excess carbohydrate to lipid in the liver, is induced in response to high-carbohydrate diet but not to fasting or a high-fat diet (Benhamed et al. 2012).”
BackgroundChrebp regulates the transcriptional activity of androgen receptor in prostate cancer
Wang, X., Wen, X., Li, R.-B., Liu, B., Qiu, G.-M., Wen, J., & Wang, Y.-M. (2014) · Tumor Biology · doi:10.1007/s13277-014-2085-8 · Cited by 12
“As a result, ablation of Chrebp in mice resulted in reduced expression of lipogenic enzymes and amelioration of obesity and hepatosteatosis [12, 13].”
BackgroundKumar, R., Chinala, A., Grandhe, D., Endicott, S. J., Garcia, M. A., Campen, M. J., & Gullapalli, R. R. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2025.126844 · Cited by 9
Zhao, Y., Li, D., Shi, H., Liu, W., Qiao, J., Wang, S., Geng, Y., Liu, R., Feng, H., Li, J., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1338465 · Cited by 19
Attenuation of obesity-induced hyperlipidemia reduces tumor growth
Hussain, A., Lian, J., Watts, R., Gutiérrez, T., Nelson, R., Goping, I. S., & Lehner, R. S. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159124 · Cited by 10
Valuing the person or valuing the role? Critique of social role valorization theory.
Elks, M. A. (1994) · PubMed · Cited by 14
Tanaka, S., Yamazaki, T., Asano, S., Mitsumoto, A., Kobayashi, D., Kudo, N., & Kawashima, Y. (2013) · Lipids · doi:10.1007/s11745-013-3839-6 · Cited by 9
“Activation of nuclear transcription factors, such as SREBP-1c, ChREBP and LXRa, is considered to contribute to the synthesis of 16:0 and 18:1n-9 through the up-regulation of FAS, SCD1 and Elovl6 [33, 34], and the increased de novo lipogenesis is secondary to the augmented expression of both SREBP-1c and ChREBP in insu…”
BackgroundInducing Effect of Clofibric Acid on Stearoyl‐CoA Desaturase in Intestinal Mucosa of Rats
Yamazaki, T., Kadokura, M., Mutoh, Y., Sakamoto, T., Okazaki, M., Mitsumoto, A., Kawashima, Y., & Kudo, N. (2014) · Lipids · doi:10.1007/s11745-014-3965-9 · Cited by 7
“Overexpression of ChREBP in the liver leads to the induction of SCD1 and specific increases in the proportions of 16:1n-7 and 18:1n-9 [48]; in the present study, however, the treatment with clofibric acid significantly decreased the gene expression of ChREBP in intestinal mucosa.”
BackgroundFlores-Ramírez, A. G., Ibarra‐Reynoso, L. D. R., Lemus, H. L. L., Olvera-Juárez, M., Luévano‐Contreras, C., & Garay‐Sevilla, M. E. (2019) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.19002995 · Cited by 8
Hosseini, M., Hashemi, S. V. A., Bagheri, M. H., Tavalaee, M., Seifati, S. M., Zohrabi, D., & Nasr‐Esfahani, M. H. (2021) · PubMed Central · doi:10.22074/ijfs.2020.134593 · Cited by 7
Immunometabolism at the crossroads of obesity and cancer—a Keystone Symposia report
Cable, J., Rathmell, J. C., Pearce, E. L., Ho, P., Haigis, M. C., Mamedov, M. R., Wu, M., Kaech, S. M., Lynch, L., Febbraio, M. A., et al. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14976 · Cited by 8
“55–58 To better understand the role of ChREBP in the liver, Postic’s group has looked at how post-translational modifications impact its function.”
Self-citationYakan, A., Özkan, H., Kaya, U., Keçeli, H. H., DALKIRAN, S., KARAASLAN, İ., Ünal, N., Akçay, A., Arslan, K., Akyüz, B., et al. (2023) · Animal Science Journal · doi:10.1111/asj.13886 · Cited by 7
Lei, K., Chen, Y., Wu, J., Lin, Y., Bai, Y., Cao, H., Che, Q., Guo, J., & Su, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142275 · Cited by 10
Metadata
- Authors
- Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., Girard, J., Guillou, H., & Postic, C.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital Saint-Antoine (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Toxicologie Alimentaire (FR)
- Institut Cochin (FR)
- Corresponding author
- Postic, Catherine
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2012-06-01
- Volume
- 122
- Issue
- 6
- Pages
- 2176-2194
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3366390
- OpenAlex
- W2117220292
- Cited by
- 408
- References
- 94
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 22 · 2023: 35 · 2022: 27 · 2021: 28 · 2020: 34 · 2019: 23 · 2018: 25 · 2017: 35 · 2016: 27 · 2015: 30 · 2014: 41 · 2013: 27 · 2012: 13
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL Portal Artxiker (Hindustan Aeronautics Limited (India)) (submittedVersion)
- Funders
- European Commission
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale (U1016)
- Association Française pour l'Etude du Foie (AFEF-2008)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- ChREBP, carbohydrate-responsive element-binding protein, hepatic steatosis, insulin resistance, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, lipogenesis, fatty acid esterification, stearoyl-CoA desaturase 1, monounsaturated fatty acids, Akt phosphorylation, insulin signaling, glucose tolerance, high-fat diet, lipidomics, hepatocytes
- MeSH terms
- Animals, Fatty Acids, Monounsaturated, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Nuclear Proteins, Phosphorylation, Stearoyl-CoA Desaturase, Transcription Factors, Metabolic Syndrome, Lipogenesis, Proto-Oncogene Proteins c-akt, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.